Abbott India Ltd | Details of CSR of the top 500 companies

Get involved in YOUR city and locality

Improve Your World

Home | About Us | Sitemap | Search | Contact Us

Also see : Corporate Social Responsibility

>> >> Details of CSR of the top 500 companies

Company: Abbott India Ltd

Income 2005-2006 = Rs 460 cr (rounded off )

Net profit before tax (05-06) = Rs 102 cr (rounded off)

Karmayog CSR Rating: 3/5

CSR activities:

We contribute to improving access to health care in the areas where our expertise, knowledge and resources will have the greatest positive impact and results for patients and for our company over the long-term. We work with many other interested stakeholders around the world – including governments, health care providers, insurers, medical groups, health professionals, patients, companies, shareholders, nongovernmental organizations, and concerned citizens – to develop solutions.

Four Core Areas

Advancing Leading-Edge Science & Technologies
We develop innovative products to address patients' unmet medical needs.
Increasing Patient Awareness
We believe in empowering people through education and information about diseases and products to help them make informed treatment decisions.
Making Our Medicines & Technologies Available
We make our pharmaceuticals, medical devices and nutritional products available through company and industry patient assistance programs. We also work with governments and others to remove underlying barriers to health care, such as the lack of infrastructure and trained personnel.
Participating in Public Policy Dialogue
We work with governments to advance sound public policy and expand patient access to health care.

Abbott is committed to the protection of human health, safety, and the preservation of the environment in all of the communities where we operate. Our annual targets for measuring environmental, health and safety performance are part of our overall management system to continually improve our performance.

EHS Standards & Policies

In the area of environment, health and safety (EHS), we focus on eliminating or reducing harmful substances and waste from manufacturing processes, training employees on EHS issues and exploring new ways to improve energy efficiency. Our 2010 performance goals, designed to reduce water usage, greenhouse gas emissions, waste, injury and accidents, is an integral part of our overall management system to continually improve our performance. By focusing on these key areas, we believe we will generate the greatest environmental and financial benefits for our company and our stakeholders.

To achieve these goals, Abbott has devoted significant resources to our environmental, health and safety (EHS) programs over the past several years. Our EHS policies and programs, which drive our performance improvements, include the following objectives:

Support the business through efficient and responsible EHS management.
Create a culture that strives for EHS performance excellence at all levels of the company.
Implement a uniform approach to risk assessments, management systems and metrics.
Incorporate information technologies to improve efficiency and support global programs.

Towards HIV In India

Kaletra® (lopinavir/ritonavir) – also called Aluvia™ – is a co-formulated, boosted protease inhibitor that is an important treatment option in the fight against HIV. In August 2006, the World Health Organization (WHO) identified heat-stable lopinavir/ritonavir (LPV/r) tablets as the recommended protease inhibitor for second-line therapy in resource-limited settings, because it is co-formulated and does not require refrigeration, which are key benefits for patients living in the developing world.

This recognition signaled global acknowledgement of the role Abbott and LPV/r will play in helping to address the HIV epidemic in the developing world. As with the previous capsule formulation, Abbott has committed to register this medicine around the world. In addition, Abbott has made a substantial investment in new manufacturing capacity to meet the increasing demand for second-line therapy from the developing world for our new LPV/r tablet. In the 114 African, least developed, low- and lower middle-income countries (as defined by the World Bank and United Nations), we have filed in the nations where 90 percent of the developing world HIV population lives.

To help ensure that all patients who need our HIV medicine can get it, Abbott has implemented five practical measures: Innovation, Broad Registration, a Lower-strength Tablet for Pediatric Use, Building Ongoing and Quality Supply, and Tiered and Affordable Pricing